Friday, July 30, 2021

Pfizer-BioNTech to seek green light for third Covid shot

The companies are also developing a Delta-specific vaccine, with clinical studies expected to begin in August.

Other News

Pfizer and BioNTech announced Thursday they would seek regulatory authorisation for a third dose of their Covid-19 vaccine.

It comes after initial data from an ongoing trial showed a third shot pushed antibody levels five to 10 times higher against the original coronavirus strain and the Beta variant, first found in South Africa, compared to the first two doses alone, according to a statement.

“The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA (Food and Drug Administration), EMA (European Medicines Agency) and other regulatory authorities in the coming weeks,” the statement said.

In addition, the companies expect that a third dose will perform similarly well against the highly transmissible Delta strain, which is quickly becoming globally dominant.

Out of caution, the companies are also developing a Delta-specific vaccine, the first batch of which has been manufactured at BioNTech’s facility in Mainz, Germany.

The companies anticipate the clinical studies will begin in August, subject to regulatory approvals.

The companies added that, based on drop-offs in efficacy seen in Israel after six months, they believe that a third dose may be needed within six to 12 months after full vaccination

“While protection against severe disease remained high across the full six months, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected,” the statement said.

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles